Copyright © Genix Pharma Private Limited, all rights are reserved.
Drugs affecting Bone
Metabolism/Orthopedics
Anti-Constipation/Laxatives
Anti-Depressants
Drugs Acting
on Urinary Tract
Lipid Lowering Agent
Brand Name: Freal
Active: Risedronate Sodium
Therapeutical Class: BMD Regulator
Indication: Postmenopausal Osteoporosis: FREAL is indicated for the treatment and prevention of Osteoporosis in postmenopausal women, In postmenopausal women with osteoporosis, FREAL reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis related fractures. Osteoporosis in Men: FREAL is indicated for treatment to increase bone mass in men with osteoporosis.